Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper – Immunotherapy of cancer

4445 - Association of tumor mutational burden with outcomes in patients with select advanced solid tumors treated with pembrolizumab in KEYNOTE-158

Date

30 Sep 2019

Session

Proffered Paper – Immunotherapy of cancer

Topics

Clinical Research;  Tumour Immunology;  Immunotherapy;  Cancer Biology

Tumour Site

Presenters

Aurélien Marabelle

Citation

Annals of Oncology (2019) 30 (suppl_5): v475-v532. 10.1093/annonc/mdz253

Authors

A. Marabelle1, M.G. Fakih2, J. Lopez3, M. Shah4, R. Shapira-Frommer5, K. Nakagawa6, H.C. Chung7, H.L. Kindler8, J.A. Lopez-Martin9, W. Miller10, A. Italiano11, S. Kao12, S.A. Piha-Paul13, J. Delord14, R.R. McWilliams15, D. Aurora-Garg16, M. Chen17, F. Jin18, K. Norwood18, Y. Bang19

Author affiliations

  • 1 Drug Development Department, Gustave Roussy, INSERM U1015, 94805 - Villejuif/FR
  • 2 Medical Oncology And Therapeutics Research, City of Hope Comprehensive Cancer Center, 91010 - Duarte/US
  • 3 Drug Development Unit, The Royal Marsden Foundation Trust and The Institute of Cancer Research, SM2 5FR - London/GB
  • 4 Medical Oncology, The Ohio State University Comprehensive Cancer Center, 43210 - Columbus/US
  • 5 Oncology Institute, Sheba Medical Center, 52621 - Ramat Gan/IL
  • 6 Medical Oncology, Kindai University Faculty of Medicine, 589-8511 - Osaka-sayama/JP
  • 7 Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 03722 - Seoul/KR
  • 8 Medicine, University of Chicago, Chicago/US
  • 9 Medical Oncology, 12 de Octubre University Hospital & Research Institute (i+12), 28041 - Madrid/ES
  • 10 Oncology, Jewish General Hospital and McGill University, Montreal/CA
  • 11 Early Phase Trials Unit, Institute Bergonié, 33076 - Bordeaux/FR
  • 12 Medical Oncology, Chris O’Brien Lifehouse, Sydney/AU
  • 13 Department Of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 77030 - Houston/US
  • 14 Medical Oncology, Institut Claudius Regaud IUCT-Oncopole, 31059 - Toulouse/FR
  • 15 Medical Oncology, Mayo Clinic, 55905 - Rochester/US
  • 16 Companion Diagnostics, Merck & Co., Inc., 07033 - Kenilworth/US
  • 17 Biostatistics And Research Decision Statistics, Merck & Co., Inc., Kenilworth/US
  • 18 Global Clinical Development, Merck & Co., Inc., 07033 - Kenilworth/US
  • 19 Hemato Oncology, Seoul National University College of Medicine, 03080 - Seoul/KR

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4445

Background

Tumor mutational burden (TMB) has been correlated with response to CTLA-4 and PD-(L)1 inhibitors. We explored the association of TMB with outcomes in cohorts A through J of KEYNOTE-158, a phase II basket study of pembrolizumab monotherapy for patients (pts) with select advanced solid tumors (NCT02628067).

Methods

Key eligibility criteria were progression on or intolerance to ≥ 1 line of standard therapy, ECOG PS 0 or 1, provision of a tumor sample for biomarker analysis, and either anal, biliary, cervical, endometrial, salivary, thyroid, or vulvar carcinoma, mesothelioma, a neuroendocrine tumor, or SCLC. Pts received pembrolizumab 200 mg Q3W for 35 cycles or until PD, intolerable toxicity, or physician or pt decision. TMB was assessed in FFPE tumor samples using the FoundationOne CDx™ assay. TMB-high was defined as 10 Mut/Mb. Primary study endpoint was ORR (RECIST v1.1, central review); DOR, PFS, OS, and safety were secondary endpoints. The relationship between antitumor activity and TMB was an exploratory endpoint.

Results

Of the 1032 pts with ≥26 weeks of follow-up as of 06 Dec 2018, 755 (73.2%) had evaluable TMB; of these, 120 (15.9%) were TMB-high, with 15/120 (12.5%) known to be MSI-H. Baseline characteristics were generally similar for TMB-high and low. There was low correlation between TMB and PD-L1 expression (ρ = 0.19). ORR (95% CI) was 28.3% (20.5-37.3) for TMB-high (24.8% [16.9-34.1] non–MSI-H) and 6.5% (4.7-8.7) for TMB-low. Median DOR was not reached for TMB-high or low (range 2.2+ to 28.8+ and 4.1 to 30.6+, respectively). Median (95% CI) PFS for TMB-high and low was 2.1 mo (2.1-3.7) and 2.1 mo (2.1-2.3), respectively; 12-mo rates were 24.3% and 14.0%. Median (95% CI) OS for TMB-high and low was 11.1 mo (8.1-16.1) and 13.3 mo (11.5-14.8), respectively; 12-mo rates were 48.0% and 52.9%. The safety profile was consistent with that previously observed for pembrolizumab.

Conclusions

TMB-high was associated with higher ORR in pts with select advanced solid tumors treated with pembrolizumab monotherapy. The tail of the PFS curve favored TMB-high. These data suggest that TMB may be predictive of the efficacy of pembrolizumab monotherapy in pts with the tumor types included in KEYNOTE-158.

Clinical trial identification

NCT02628067, December 11, 2015.

Editorial acknowledgement

Melanie Leiby of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Legal entity responsible for the study

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Funding

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Disclosure

A. Marabelle: Research grant / Funding (institution), principal investigator: Roche/Genentech, BMS, Merck (MSD), Pfizer, Lytix pharma, Eisai, AstraZeneca/MedImmune, Tesaro, Chugai ; Research grant / Funding (institution): MSD; Travel / Accommodation / Expenses: MSD, AstraZeneca, Roche/Genentech, BMS ; Research grant / Funding (institution), rincipal investigator, sponsor Unicancer; ACSE NIVOLUMAB/NCT03012581 : INCa, Ligue contre le Cancer & BMS; Research grant / Funding (institution), principal investigator, sponsor Leon Berard Cancer Center; ISIJX/NCT02977156: Transgene; Research grant / Funding (institution), principal investigator, sponsor Gustave Roussy; NIVIPIT/NCT02857569 : BMS; Research grant / Funding (institution), principal investigator, sponsor Gustave Roussy; PEMBIB/NCT02856425 : Boehringer Ingelheim; Research grant / Funding (institution): Astrazeneca, BMS, Boehringer Ingelheim, Janssen Cilag, Merck, Novartis, Pfizer, Roche, Sanofi ; Non-remunerated activity/ies, drug supply: AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Johnson & Johnson, Lilly, MedImmune, Merck, NH TherAGuiX, Pfizer, Roche ; Advisory / Consultancy: GSK, AstraZeneca; Advisory / Consultancy: Oncovir, Inc.; Advisory / Consultancy: Innate Pharma, Merck Serono, eTheRNA, Lytix pharma, Kyowa Kirin Pharma, Bayer, Novartis, BMS, Symphogen, Genmab, Amgen, Biothera, Nektar, GSK, Oncovir, Pfizer, Seattle Genetics, Flexus Bio, Roche/Genentech, OSE immunotherapeutics, Transgene, Gritstone, ; Speaker Bureau / Expert testimony: Roche/Genentech, BMS, Merck (MSD), Merck Serono, AstraZeneca/MedImmune, Amgen, Sanofi ; Advisory / Consultancy: Roche, Pierre Fabre, Onxeo, EISAI, Bayer, Genticel, Rigontec, Daiichi Sankyo, Imaxio, Sanofi, BioNTech, Corvus, GLG, Deerfield, Guidepoint Global, Edimark, System Analytics, imCheck, Sotio, Bioncotech, Molecular Partners, Pillar Partners, Boehringer Inge; Shareholder / Stockholder / Stock options: Pegascy SAS (Gustave Roussy Spin Off for Drug Repositioning) ; Research grant / Funding (institution): Merus, BMS, Boehringer Ingelheim, Transgene, Fondation MSD Avenir; Officer / Board of Directors, supervisory board member: Gustave Roussy Foundation; Advisory / Consultancy, steering committee of the immuno-oncology task force: Unicancer; Research grant / Funding (institution), sub-investigator of clinical trials: Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca, Aveo, Bayer Healthcare Ag, Bbb Technologies Bv, Beigene, Bioalliance Pharma, Biontech Ag, Blueprint Medicines, Boehringer Ingelheim, Bristol; Licensing / Royalties, Patent Issued (not licensed yet) : “Humanized and Chimeric Monoclonal Antibodies to CD81”, Stanford Office of Technology Licensing, 3000 El Camino Real, Bldg. 5, Suite 300, Palo Alto, CA 94306-2100. U.S. Application Serial No. 62/351,054. M.G. Fakih: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Amgen; Advisory / Consultancy: Array; Advisory / Consultancy: Bayer; Research grant / Funding (self): AstraZeneca; Research grant / Funding (self): Novartis; Research grant / Funding (institution): MSD. J. Lopez: Advisory / Consultancy: Genmab; Advisory / Consultancy: Novartis; Research grant / Funding (institution): MSD; Research grant / Funding (institution): Roche/Genentech; Research grant / Funding (institution): Basilea. M. Shah: Research grant / Funding (institution): MSD. R. Shapira-Frommer: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): MSD; Honoraria (self): BMS; Honoraria (self): Roche; Honoraria (self): Novartis; Honoraria (self): Medison; Advisory / Consultancy: Clovis Oncology. K. Nakagawa: Research grant / Funding (institution): MSD. H.C. Chung: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Merck Serono; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Lilly; Honoraria (self): Foundation Medicine; Advisory / Consultancy, Research grant / Funding (institution): Taiho; Advisory / Consultancy: Celltrion; Advisory / Consultancy, Research grant / Funding (institution): MSD; Advisory / Consultancy: Quintiles; Advisory / Consultancy: BMS; Research grant / Funding (institution): GSK; Research grant / Funding (institution): BMS-ONO. H.L. Kindler: Research grant / Funding (institution): MSD. J.A. Lopez-Martin: Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: MSD; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: BMS; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Advisory / Consultancy: Pierre Fabre; Advisory / Consultancy: Celgene; Advisory / Consultancy: Amgen; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Lilly; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options: PharmaMar; Advisory / Consultancy: Chobani. W. Miller: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): BMS; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Merck; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Roche; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): GSK; Research grant / Funding (institution): MSD; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Methylene; Research grant / Funding (institution): MedImmune; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Astellas. A. Italiano: Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy: Epizyme; Advisory / Consultancy: ImmuneDesign; Advisory / Consultancy: Lilly; Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy, Research grant / Funding (institution): MSD; Advisory / Consultancy: Novartis; Advisory / Consultancy, Research grant / Funding (institution): Roche; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): PharmaMar. S. Kao: Research grant / Funding (institution): MSD. S.A. Piha-Paul: Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): Aminex Therapeutics; Research grant / Funding (institution): BioMarin Pharmaceutical, Inc; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Cerulean Pharma Inc.; Research grant / Funding (institution): Chugai Pharmaceutical Co., Ltd; Research grant / Funding (institution): Curis; Research grant / Funding (institution): Five Prime Therapeutics; Research grant / Funding (institution): Flex Bio, Inc; Research grant / Funding (institution): Genmab A/S; Research grant / Funding (institution): GlaxoSmithKline; Research grant / Funding (institution): Helix BioPharma Corp; Research grant / Funding (institution): Incyte Corp; Research grant / Funding (institution): Jacobio Pharmaceuticals Co., Ltd; Research grant / Funding (institution): MedImmune, LLC; Research grant / Funding (institution): Medivation, Inc.; Research grant / Funding (institution): Merck Sharp and Dohme Corp; Research grant / Funding (institution): NewLink Genetics Corporation/Blue Link Pharmaceuticals; Research grant / Funding (institution): Novartis Pharmaceuticals; Pieris Pharmaceuticals, Inc.; Pfizer; Principia Biopharma, Inc.; Puma Biotechnology, Inc.; Seattle Genetics; Taiho Oncology; Tesaro, Inc.; TransThera Bio; XuanZhu Biopharma. J. Delord: Honoraria (self), Advisory / Consultancy: Merck; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): BMS; Honoraria (self), Research grant / Funding (institution): MSD; Advisory / Consultancy: EMD Serono; Research grant / Funding (institution): Genentech; Research grant / Funding (institution): AstraZeneca. R.R. McWilliams: Advisory / Consultancy: Ipsen; Advisory / Consultancy: NewLink Genetics; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): MSD. D. Aurora-Garg: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck Sharp & Dohme Corp. M. Chen: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck Sharp & Dohme Corp. F. Jin: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck Sharp & Dohme Corp. K. Norwood: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck Sharp & Dohme Corp. Y. Bang: Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Genentech/Roche; Advisory / Consultancy, Research grant / Funding (institution): MSD; Advisory / Consultancy, Research grant / Funding (institution): Merck Serano; Advisory / Consultancy: Bayer; Advisory / Consultancy, Research grant / Funding (institution): BMS; Advisory / Consultancy, Research grant / Funding (institution): Eli Lilly; Advisory / Consultancy, Research grant / Funding (institution): Taiho; Advisory / Consultancy, Research grant / Funding (institution): Daiichi-Sankyo; Advisory / Consultancy, Research grant / Funding (institution): Astellas; Advisory / Consultancy, Research grant / Funding (institution): BeiGene; Advisory / Consultancy, Research grant / Funding (institution): GreenCross; Advisory / Consultancy: Biopharm; Advisory / Consultancy: Hanmi; Advisory / Consultancy, Research grant / Funding (institution): Genexine; Research grant / Funding (institution): GSK; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): MacroGenics, Boston Biomedical, FivePrime, Curis, Takeda, Ono, CKD Pharma.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.